Symbolbild · KI-generiert
ProKidney Corp.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
ProKidney is a biopharmaceutical company developing cell-based therapies for the treatment of chronic kidney disease. The lead product REACT is based on the patient's own kidney cells and is intended to stabilise or improve renal function. The company is in the clinical development stage.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| ProKidney Corp. | PROK | NASDAQ | 465 Mio. USD |
| Q32 Bio Inc. | QTTB | NASDAQ | 467 Mio. USD |
| Aquestive Therapeutics, Inc. | AQST | NASDAQ | 464 Mio. USD |
| Fulgent Genetics, Inc. | FLGT | NASDAQ | 470 Mio. USD |
| Varex Imaging Corporation | VREX | NASDAQ | 471 Mio. USD |
| Valneva SE | VALN | NASDAQ | 472 Mio. USD |
| Shoulder Innovations, Inc. | SI | NYSE | 472 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.